A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas

Complete Title: A Phase 1/2 Study of CPI-0209 Monotherapy and in Combination with Other Therapy in Patients with Advanced Tumors

Trial Phase: I/II

Investigator: Kalyan Banda

First-in-human, open-label, sequential dose escalation and expansion study of CPI-0209 in patients with advanced solid tumors and lymphomas. CPI-0209 is a small molecule inhibitor of EZH2.

Keywords:

Mesothelioma
Prostate Cancer
Lymphoma, T-Cell
Lymphoma, Large B-Cell, Diffuse
Advanced Solid Tumors

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Join a Clinical Trial

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.

Contact Us

If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.